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Simvastatin in nephrotic syndrome. an increase of the glomerular filtration rate [8] following
Background. Hyperlipidemia of the nephrotic syndrome is treatment by the HMG CoA-reductase inhibitors sim-
a risk factor for the development of systemic atherosclerosis, vastatin or lovastatin, respectively. In a prospective andbut it also may aggravate glomerulosclerosis and enhance the
randomized study of a similiar patient group, lipid low-progression of glomerular disease. HMG-CoA reductase inhib-
ering therapy by simvastatin was not accompanied byitors are effective in reducing cardiovascular morbiditiy and
mortality. Whether they may influence the progression of glo- significant changes in proteinuria and GFR [9]. Unfortu-
merular disease is not clear. The Simvastatin in Nephrotic nately, the number of patients was too small and the
Syndrome Study addressed the question of whether or not observation time of 24 weeks was too short to demon-cholesterol lowering by the HMG-CoA reductase inhibitor
strate significant differences.simvastatin was superior to placebo treatment in limiting the
The available studies do not provide a conclusive an-decline of GFR and reducing proteinuria in nephrotic patients
with primary glomerulonephritis. swer to the question of whether or not a lipid lowering
Methods. This was a prospective, two-year, double-blind therapy ameliorates the progression of glomerular dis-
trial that included 56 patients with primary glomerulonephritis,
eases. Therefore, we initiated a multicenter, long-term,hypercholesterolemia due to the nephrotic syndrome (protein-
double-blind, placebo controlled study, to assess the ef-uria .3 g/24 hr), and a creatinine clearance .40 ml/min/1.73
m2. They were randomly assigned to treatment with simvastatin fect of a cholesterol lowering therapy with simvastatin on
or placebo targeted to achieve low density lipoprotein (LDL) renal function and proteinuria in hypercholesterolemic
cholesterol levels below 120 mg/dl. The objectives were to patients with idiopathic glomerulonephritis and a ne-
determine the efficacy and safety of simvastatin, the rate of
phrotic syndrome. We found simvastatin to be an effec-GFR decline as measured by inulin clearance, and the change
tive cholesterol lowering drug reducing LDL cholesterolin proteinuria over a two-year treatment period.
Results. Simvastatin produced a mean change in cholesterol, by approximately 35%, and the Scandinavian Simvastin
LDL cholesterol, high density lipoprotein (HDL) cholesterol Survival Study Group (4S Group) found that it has an
and triglycerides of 239%, 2 47%, 1 1%, and 230%, respec- excellent safety profile in long-term treatment [10].
tively. Serum lipoprotein(a) [Lp(a)] was not affected. No major
simvastatin related events occurred. Minor events included
elevations in serum creatine kinase without clinical symptoms. PATIENTSThe course of renal function and of proteinuria during the
study are still under evaluation and are not given here. Patients with focal segmental glomerulosclerosis,
Conclusions Long-term treatment with simvastatin in ne- membranous nephropathy, membranoproliferative glo-
phrotic patients with hypercholesterolemia is effective and safe. merulonephritis, or IgA nephropathy were recruited
from 40 renal clinics in Germany. Inclusion criteria were:
proteinuria .3 g/24 hr at least during the last 6 months
Hyperlipidemia is common in patients with glomerular prior to inclusion; creatinine clearance .40 ml/min/
disease, and pharmacological correction of hyperlipid- 1.73 m2; low density lipoprotein (LDL) cholesterol .4.2
emia complicating experimentally-induced renal disease mmol/liter (160 mg/dl) prior to randomization while off
in rats was found to markedly ameliorate glomerular all lipid-lowering drugs; and adhearing to an appropriate
injury [1–6]. In hypercholesterolemic patients with dif- diet for at least four weeks. The primary exclusion crite-
ferent nondiabetic glomerulopathies and a nephrotic ria were: systolic blood pressure .160 mm Hg or diastolic
syndrome, two small, uncontrolled short-term studies blood pressure .95 mm Hg despite treatment; concur-
found either a significant reduction of albuminuria [7] or rent use of corticosteroids, immunosuppressive drugs, or
nonsteroidal anti-inflammatory drugs; diabetes mellitus;
concurrent use of other lipid lowering drugs; unstableKey words: low density lipoprotein, cholesterol, progressive renal dis-
ease, hyperlipidemia. renal function defined as changes in serum creatinine
.176 mol/liter (.2 mg/dl) in the previous four months. 1999 by the International Society of Nephrology
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Fig. 1. Disposition of patients showing each
phase of screening and study.
Concurrent use of dihydropyridine calcium channel- function, and to identify patients with rapidly progressive
blockers was an exclusion criterion, since experimental disease. During the baseline measurement period all pa-
and preliminary clinical evidence indicated its detrimen- tients met the inclusion/exclusion criteria. The choles-
tal effect on renal function. At the time of study planning, terol intake was reduced to 200 mg/day and protein in-
there was preliminary evidence for an ameliorating effect take to 0.6 to 0.8 g per kg body weight per day by
of ACE inhibitors on the progression of glomerular dis- appropriate counseling and repeated reinforcement.
eases. Hence, we accepted individual decisions of investi- Protein intake was monitored by examining urine urea
gators to introduce ACE inhibitor therapy six months excretion, and 90% of the patients had a protein intake
prior to randomization. Initiation of ACE inhibitor treat- between 0.7 and 0.9 g/kg/day during the study period.
ment during later study periods was an exclusion crite- At six, four, and two months prior to randomization the
rion. Enalapril was the recommended ACE inhibitor. patients underwent clinical and laboratory examinations
including safety parameters, proteinuria, creatinine clear-
ance, lipid levels and blood pressure. At the end of theSTUDY DESIGN
placebo baseline period all eligible patients were random-This was a multicenter, two-year, double blind, pla-
ized to receive one tablet of 10 mg simvastatin or placebo.cebo controlled study with the option of an extension
At the follow-up visits the dosage of simvastatin was ad-based on a decision of the steering committee after a one
justed in 10 mg and 20 mg increments, to lower the LDL-year interim analysis. It consisted of a 20-week baseline
cholesterol to less than 120 mg/dl. The maximum dosageperiod, followed by a 4-week placebo baseline period,
was 40 mg of simvastatin. The lipid values were measuredand the active treatment period (Fig. 1). The rationale
by the core laboratory and were not provided to eitherof the long baseline was to identify patients going into
remission, to establish the pretreatment course of renal the investigator or the patient. The increase in dosage
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Table 1. Baseline characteristics of randomized patients tients (13 in the simvastatin group) received enalapril
according to study group
throughout the study. The mean diastolic blood pressure,
Simvastatin Placebo averaged over all follow-up visits, was 86 6 5 mm Hg
Variable (N 5 20) (N 5 23) in the simvastatin group and 88 6 6 mm Hg in the placebo
Mean (sd) age years 43.8 (10.7) 42.8 (14.8) group. The corresponding values of the systolic pressure
Sex male/female 13/7 18/5
were 137 6 13 mm Hg and 138 6 7 mm Hg, respectively.Body mass index kg/m2 25.7 (3.9) 26.3 (4.7)
Mean (sd) renal function indicators Blood chemistry including liver enzymes, bilirubin, alka-
GFR ml/min per 1.73 m2 80.4 (28.5) 90.9 (43.1) line phosphatase, serum electrolytes, uric acid, TSH, cho-
Creatinine clearanace ml/min per 1.73 m2 85.9 (33.0) 85.6 (30.0)
linesterase, thyroxin, T4, and a complete blood countSerum creatinine:a lmol/liter 118 (45) 110 (32)
Urinary protein excretionb g/24 hr 5.9 (2.5) 7.4 (3.9) were in normal ranges throughout the study.
Urinary protein excretion/creatine 4.11 (1.74) 4.97 (2.31)
Mean (sd) arterial blood pressure mm Hg
Systolic 139.0 (18.3) 136.1 (10.8) LIPID VALUES AND ADVERSE EVENTS
Diastolic 86.4 (7.9) 85.5 (8.4)
Mean 103.9 (9.3) 102.4 (7.0) After nine months on the study drug, the patients
Mean (sd) serum biochemistry received on average 35 mg of simvastatin in order to
Serum total protein mg/dl 5.90 (8.76) 6.57 (7.74)
achieve the treatment goal of serum LDL cholesterolPlasma cholesterolc mmol/liter 9.42 (3.37) 8.66 (1.91)
Plasma triglyceride mmol/liter 2.80 (1.42) 2.90 (1.58) below 3.1 mmol/liter (120 mg/dl). The mean changes
LDL cholesterol mmol/liter 5.95 (1.61) 6.17 (1.83) from baseline in total, LDL, and high density lipoproteinHDL cholesterolc mmol/liter 1.61 (0.64) 1.26 (0.46)
(HDL) cholesterol, and serum triglycerides were 239%,Lipoprotein(a)c mg/dl 39.6 (34.4) 39.2 (41.3)
Renal disease number of patients 247%, 11%, and 230%. Serum Lp(a) was not affected
FSGS 4 6 in either group. Simvastatin was well tolerated and noMGN 7 7
major drug related events or deaths occurred. A numberMPGN 6 4
IgA-N 3 6 of minor events were reported, including elevations in
Abbreviations are: FSGS, focal and segmental glomerulosclerosis; MGN, serum creatine. Overall, creatine kinase values were
membranous glomerulonephritis; MPGN, membrano proliferative glomerulone- fluctuating in simvastatin and placebo treated patients,phritis; IgA-N, IgA-nephropathy.
a To convert to mg/dl divide by 88.4 but elevations of the enzyme were not accompanied by
b Urinary protein excretion is mean of three baseline measurements before clinical symptomsrandomisation
c To convert to mg/dl divide by 0.02586
d To convert to mg/dl divide by 0.01129
DISCUSSION
Simvastatin decreased the total and LDL cholesterol
by 239% and 247%, respectively. The drop in serumwas issued by the core laboratory. For each increase in
lipids exceeded that reported with statin therapy in otherthe simvastatin group, a matched patient in the placebo
studies, including patients with a nephrotic syndromegroup received an appropriate increase in the placebo
and constant proteinuria [8, 9] and in patients of the 4Sdose. Follow-up visits were scheduled in monthly inter-
Group [10]. The surprisingly high decrease of 230% invals during the first three months and in six week inter-
triglycerides was not related to the dietary counseling,vals thereafter. The inulin single-shot plasma clearance
since the placebo group with identical dietary advice hadwas measured at the end of the placebo baseline period
a change in triglycerides of only 25% at two years.and in six month intervals thereafter [11].
Further analysis of the data should provide evidence as
to whether simvastatin has a potent triglyceride lowering
PATIENT RECRUITMENT, BASELINE action in nephrotic syndrome. The effective long-term
CHARACTERISTICS, AND FOLLOW-UP lowering of LDL is providing a solid base to assess the
effect of a cholesterol lowering therapy on renal functionBetween May 1991 and June 1994 approximately 800
and proteinuria. Despite major efforts, including thepatients with a nephrotic syndrome were screened and
screening of approximately 800 patients with a nephrotic102 patients were included in the six-month baseline
syndrome, only 56 patients could be randomized due toperiod. Thereafter, 56 patients were randomized; 46 pa-
the stringent inclusion and exclusion criteria, and only 43tients were not eligible according to study criteria. Thir-
patients completed the two-year study period. The smallteen patients had to be excluded from the per-protocol
number of patients may be a limitation of the study. Itpopulation (Fig. 1). After two years 43 patients com-
was our goal to have at least 40 patients in each group atpleted the study. Only 14 patients entered the third study
the end of the study. Blood pressure was well controlledyear. Data are given for the two-year study period. The
during the study. Dihydropyridine calcium channel block-baseline characteristics of the groups were similiar (Ta-
ers were excluded from antihypertensive treatment, sinceble 1). All patients except two in the simvastatin group
were on antihypertensive treatment. Twenty-seven pa- some studies have shown increasing proteinuria and little
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